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1. Introduction
Radiologic techniques play an integral role in the diagnosis and management of patients
with inflammatory bowel disease (IBD). Imaging has long been utilized to evaluate seg‐
ments of the digestive tract that are inaccessible to conventional endoscopy. While endos‐
copy offers unparalleled visualization of the large bowel lumen and biopsy capabilities, the
small bowel remains essentially wholly inaccessible by conventional endoscopic techniques
[1]. Thus, one important role that imaging plays in the care of patients with IBD is the evalu‐
ation of the small bowel.
With the advancement of cross-sectional imaging techniques such as computed tomography
(CT) and magnetic resonance imaging (MRI), the role of imaging in IBD has greatly expanded
to include the mucosal, transmural, extraluminal, and extra-intestinal manifestations of these
diseases. Imaging now not only assists in making the diagnosis of IBD, including helping to
discriminate between ulcerative colitis and Crohn’s disease, but also is a critical component in
the determination of active versus indolent disease. Imaging assessment of IBD activity is in‐
creasingly being utilized by surgeons and gastroenterologists for treatment planning and as a
biomarker of treatment response/resistance. Urgent and emergent complications of IBD in‐
cluding abscesses, fistulae, perforations, obstructing strictures, and toxic megacolon are also
best detected by cross-sectional imaging techniques over endoscopic methods [2]. Imaging is
pivotal in the identification of extra-intestinal involvement of IBD, processes that both pro‐
vide important adjunctive data in the diagnosis of IBD as well as contribute significantly to the
morbidity and mortality of IBD. Techniques such as MRI that provide superior soft tissue con‐
trast  allow for both the improved visualization of the perianal disease manifestations of
Crohn’s disease such as fistulae and abscesses, as well as the precise anatomic localization for
treatment planning [3]. Moreover, as our understanding of the pathophysiologic underpin‐
nings of IBD continually expands, novel molecular imaging approaches have been applied to
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highlight the specific intra-cellular perturbations occurring within the bowel and thus identify
areas of pathology with unparalleled resolution and specificity.
Multiple radiologic modalities, including fluoroscopy, CT, MRI, ultrasound, and nuclear
medicine/molecular imaging techniques, have been applied towards imaging IBD. In this
chapter, we will discuss technical considerations, appropriate indications, and key imaging
findings for the most common imaging modalities currently applied in the care of patients
with IBD. We will also discuss the risks attendant to the use of ionizing radiation, imaging
findings of the extra-intestinal manifestations of IBD, and the potential role that molecular
imaging may play in the future for patients with IBD.
2. Fluoroscopic imaging
2.1. Indications
Fluoroscopic imaging historically has been considered as the “gold standard” approach to
imaging the small bowel. Despite the promotion of newer endoscopic technologies such as
video capsule endoscopy and double balloon endoscopy, as well as the development of
cross-sectional methods such as CT and MR enterography, fluoroscopy remains a staple tool
for the identification of small bowel pathology, particularly pathology involving the termi‐
nal ileum. The benefits of fluoroscopic imaging include the ability to visualize peristaltic
loops of small bowel in real time, a feature that allows for the discrimination between true
abnormalities and transient changes in configuration related to motion. Additionally, with
optimal contrast opacification, inspection of the mucosal surface of the entire length of the
small bowel in relief is feasible. The examination may be performed as either a small bowel
follow through, in which oral contrast is administered, or as a small bowel enteroclysis, in
which the patient undergoes nasojejunal intubation followed by catheter instillation of both
positive and negative contrast agents at a controlled rate. Advantages of the latter include
more uniform distention and opacification of the entire small bowel leading to enhanced de‐
tection of segmental strictures and mucosal disease from double contrast opacification. En‐
teroclysis is particularly useful in patients with intermittent symptoms of IBD, as the
complete distention of the small bowel can provoke correlative imaging findings which may
otherwise go undetected with a standard oral contrast preparation in a small bowel follow
through. Significant disadvantages of enteroclysis are invasiveness and patient discomfort.
Though fluoroscopic examination of the small bowel is still widely used, trans- and extra‐
mural disease are poorly detected with this technique. Moreover, the exposure of patients to
ionizing radiation with this modality should be taken into consideration, particularly in pa‐
tients who are likely to undergo frequent imaging examinations.
2.2. Technical considerations
In fluoroscopic imaging, conventional two-dimensional radiographs are obtained with the
patient lying on an examination table. The patient is kept nil per os (NPO) for several hours
prior to the examination; a bowel cleansing regimen is rarely employed. Bowel visualization
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is achieved following the administration of radio-opaque contrast agents, a large class of sol‐
utions that generally contain varying concentrations of barium. The benefits of fluoroscopic
imaging include the ability to visualize peristaltic loops of small bowel in real time, a feature
that allows for the discrimination between true abnormalities and transient changes in con‐
figuration related to motion. Additionally, with optimal contrast opacification, inspection of
the mucosal surface along the entire length of the small bowel in relief is feasible. The pa‐
tient’s position can be adjusted by the fluoroscopist to any desirable obliquity with respect
to the X-ray source so that the outline of every loop of small bowel is visualized. The fluoro‐
scopist also employs compressive maneuvers using paddles, balloons, and gloves to spread
out the loops of bowel so that they are individually visible.
In a small bowel follow through, the patient is asked to drink approximately 500cc of a bari‐
um containing oral contrast solution. Serial spot radiographs are obtained until the bolus
has passed the terminal ileum into the cecum; this takes approximately 45-60 minutes,
though pro-peristaltic agents such as metoclopramide may be administered to accelerate the
process. Fluoroscopy with compression is then performed to identify areas of pathology.
In enteroclysis, a naso-jejunal catheter is placed such that the tip of the catheter terminates in
the proximal jejunum, distal to the ligament of Treitz. A barium-containing solution is then
infused at a uniform rate through the catheter. One variation is to infuse methylcellulose af‐
ter a small amount of barium; this “double contrast” technique offers an improved inspec‐
tion of the mucosal surface pattern [4]. Advantages of naso-jejunal intubation include
bypassing the regulatory mechanisms of the pylorus and a more uniform distention and
opacification of the entire small bowel, particularly in patients who are unable to drink an
adequate volume of contrast by their own volition. Enteroclysis is particularly effective in
provoking radiographic evidence of low-grade partial obstructions in patients with intermit‐
tent symptoms, findings that may have been undetectable by small bowel follow through.
The process of naso-jejunal intubation and infusion of contrast, however, can be very un‐
comfortable, and in some cases intolerable, for patients; some institutions provide conscious
sedation for that reason.
2.3. Interpretation of imaging findings
Much of the fluoroscopic imaging of UC, which predominantly involves the large bowel,
has been replaced by colonoscopy. However, approximately 20% of patients with severe UC
have associated “backwash” ileitis. Fluoroscopy demonstrates a patulous, incompetent ileo‐
cecal valve with a granulated mucosal relief pattern of the terminal ileum. This finding is in
contrast to Crohn’s disease, which is characterized by a stenotic ileocecal valve with luminal
narrowing and ulceration of the terminal ileum. Backwash ileitis usually resolves following
total colectomy [5].
Crohn’s disease can affect the digestive tract anywhere from the mouth to the anus; approxi‐
mately 80% of these patients have small bowel involvement (Figure 1). Unlike UC, “skip
areas” of uninvolved bowel may be interspersed between segments of affected bowel. How‐
ever, Crohn’s disease has a predilection for affecting the terminal ileum. The earliest radio‐
graphic sign of Crohn’s disease is aphthous ulcers, which appear as shallow collections of
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contrast with surrounding radiolucent haloes due to adjacent mucosal edema. Aphthous ul‐
cers are not specific to Crohn’s disease and may be seen in a number of diseases. However,
as Crohn’s disease progresses, the ulcers coalesce to form linear, curvilinear, or spiculated
areas of ulceration along the mesenteric border of the small bowel. There is resultant retrac‐
tion of the bowel wall, leading to pseudodiverticula and pseudosacculation of the anti-mes‐
enteric bowel wall. These active inflammatory changes can lead to intermittent small bowel
obstruction, which is best diagnosed by enteroclysis technique. Severe disease produces a
classic “cobblestone” appearance, with deep transverse and longitudinal ulcerations bor‐
dered by areas of edema creating a checkered mucosal relief pattern. Chronic Crohn’s dis‐
ease leads to circumferential bowel wall thickening and irreversible stricture formation.
Figure 1. Fluoroscopic imaging findings in Crohn’s disease. A, Aphthous ulcers, which appear as focal collections of
contrast with surrounding haloes of mucosal edema, are present in early Crohn’s disease (red arrow). B, Progressive
disease results in longitudinal ulcerations on the mesenteric bowel surface with pseudosacculation formation on the
anti-mesenteric surface. C, Severe disease can have a “cobblestone” mucosal relief pattern due to intersecting trans‐
verse and longitudinal ulcers.
Though fluoroscopic examination of the small bowel is still widely used, trans- and extra‐
mural disease are poorly detected with this technique. Moreover, the exposure of patients to
ionizing radiation with this modality should be taken into consideration, particularly in pa‐
tients who are likely to undergo frequent imaging examinations.
3. Computed tomographic imaging
3.1. Indications
Computed tomography remains the work-horse imaging modality for IBD and its complica‐
tions in the United States. As a high-resolution cross-sectional technique, CT can visualize
not only the bowel lumen, but also the bowel wall, visceral fat, intra-abdominal lymph no‐
des, and mesenteric vasculature supplying the bowel. Extraintestinal disease manifestations
such as nephrolithiasis, sacroiliitis, and primary sclerosing cholangitis can readily be evalu‐
ated. Computed tomography can additionally be performed rapidly, and CT scanners are
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present in most emergency rooms, rendering it an ideal choice in the urgent or emergent set‐
ting. As such, CT is an appropriate imaging examination for the diagnosis of IBD, the evalu‐
ation of response to intervention including post-surgical changes, and the detection of
urgent and emergent complications such as abscess formation and acute bowel obstruction.
However, since subtle mucosal ulcerations are not well visualized by CT, this modality
should not be used as a first line approach for the detection of suspected mild disease.
3.2. Technical considerations
The past two decades have witnessed a revolution in the technology of CT scanners. The in‐
troduction of the helical CT scanner has permitted the acquisition of volumetric data sets in
a continuous, uninterrupted manner. The source data are obtained with sub-millimeter slice
thickness, so that images may be be reconstructed from the source axial plane into standard
coronal or sagittal planes, or any other plane desired by the radiologist. Also, the advent of
multidetector row scanners, initially with 4-slice devices in 1998, followed by 8-, 16-, 64-,
and most recently 320-slice devices, has had a dramatic effect on reducing scanning time.
This, in turn, has shortened the requisite breath hold for the patient, making the examina‐
tion more comfortable and less often degraded by respiratory motion artifact [6].
There exist a variety of CT protocols for abdominal indications. With regards to IBD, a com‐
mon reason to pursue imaging is for the assessment of small bowel pathology. CT enterog‐
raphy is usually the imaging protocol of choice, which combines large volume enteral
contrast distention of small bowel with intravenous contrast administration. For this imag‐
ing examination, patients are kept NPO for several hours prior; similar to fluoroscopy, a
bowel cleansing regimen is not routinely required. Intravenous contrast is always used
when possible. Enteral contrast is an indispensible component of the technique. Initial CT
enterography relied on “positive” enteral contrast agents, usually barium containing solu‐
tions whose higher attenuation characteristics opacify the bowel lumen. However, differen‐
tiating the thin line of mucosal enhancement due to intravenous contrast from the opaque
enteral contrast in the bowel lumen can be challenging. Therefore, a more popular approach
is to use “neutral” enteral contrast agents that distend but do not opacify the bowel lumen.
In this manner, mucosal enhancement patterns are better seen, as are areas of non-distensi‐
bility such as strictures. Water is a commonly used neutral enteral agent, but since this has
the disadvantage of being absorbed by the body, commercially available preparations that
are isodense to water on CT imaging but are non-absorbable are also prevalent [7]. Essential‐
ly all current CT enterography protocols utilize neutral enteral contrast.
The volume of enteral contrast administered to the patient and the duration over which they
are asked to ingest contrast vary by institution. However, the overall goal is to maximize
uniform distention of the small bowel, which typically requires 1000-1500 mL of contrast.
Patients are first instructed to drink the enteral contrast, generally over approximately 45 to
60 minutes. They then lie down on the CT scanner; intravenous contrast is administered;
originally CT enterography studies were scanned at 55-60 seconds post-contrast (entero‐
graphic phase) coinciding with peak superior mesenteric artery enhancement. However,
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many institutions now perform scanning during portal venous phase (~70 seconds) for opti‐
mal visceral organ evaluation.
The CT analog to fluoroscopic enteroclysis, known at CT enteroclysis, is also used as a meth‐
od to achieve optimal luminal filling. A naso-jejunal tube is required and is usually inserted
in a fluoroscopy suite. Contrast is administered under fluoroscopic guidance, after which
the patient is transported to the CT scanner. Unlike fluoroscopy, though, a real-time assess‐
ment of bowel distensibility cannot be made by CT, as the patients are usually only imaged
after the contrast has been fully administered. The disadvantage of patient discomfort
caused by naso-jejunal intubation is no different.
For patients suspected of bowel obstruction or perforation, oral contrast is frequently contra‐
indicated and traditional CT imaging with IV contrast only is recommended.
An important concern with CT is the use of ionizing radiation. Recent studies suggest that
CT exams account for the vast majority of ionizing radiation exposure to IBD patients from
imaging, especially among patients diagnosed at an early age. An informed analysis of the
associated risks, especially for the pediatric patient, should be performed prior to each ex‐
amination.
3.3. Interpretation of imaging findings – Crohn’s disease
A principal clinical question for which CT is utilized in IBD is the determination of active
versus inactive disease in the small bowel. This distinction is of high clinical significance: pa‐
tients with active inflammation are treated medically with immuno-modulatory therapy,
while symptomatic patients with inactive, fibrosed strictures often require surgical interven‐
tion. Areas of actively inflamed bowel on CT most commonly demonstrate pathologic bowel
thickening, which is defined as bowel wall greater than 3mm in thickness. A 3mm cutoff
was selected by consensus as the best compromise between sensitivity and specificity and is
for the most part used universally for all cross-sectional modalities including MRI and ultra‐
sound. Another differentiating characteristic of active disease is mucosal hyperenhance‐
ment, which appears as a pencil-thin line outlining the luminal surface of the bowel wall
and reflects the hyperemia of inflammation (Figure 2A). This finding is considered the most
sensitive for active disease, and the degree of hyperenhancement may correlate with the de‐
gree of underlying inflammation. Active inflammation also results in submucosal edema,
which manifests on CT examination as a lower attenuation submucosal layer interposed be‐
tween mucosal and serosal layers. This mural stratification is also referred to as the “target
sign” due to its characteristic appearance (Figure 2C). The most specific feature for active
Crohn’s disease is engorgement of the vasa recta adjacent to an inflamed loop of bowel, a
finding known as the “comb sign” (Figure 2B). Secondary signs for active inflammation in‐
clude mesenteric fat stranding, focal ascites adjacent to bowel, and lymphadenopathy. Of
note, while mucosal hyperenhancement and abnormal bowel thickening are frequent fea‐
tures of active Crohn’s disease, they are not specific and may be seen in infectious enteritis
or mesenteric ischemia. Similarly, mural stratification can be seen in UC as well as bowel
ischemia. On the other hand, the “comb sign” is considered fairly specific for Crohn’s dis‐
ease [2, 7].
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Figure 2. CT findings in acute Crohn’s disease. A, Active inflammation causes mucosal hyperenhancement and bowel
wall thickening greater than 3mm. B, Engorgement of the vasa recta adjacent to an inflamed loop of bowel is a specif‐
ic finding in active Crohn’s disease and has been coined the “comb sign.” C, Submucosal edema yields a characteristic
“target sign.”
The presence of mucosal hyperenhancement, abnormal bowel wall thickening, mural strati‐
fication, and prominent adjacent vasa recta in an area of poorly distensible bowel suggests
that the stricture is due to active inflammation and is thus potentially reversible by medical
interventions. The strictures of chronic Crohn’s disease, in contrast, are fibrotic, irreversible,
and do not demonstrate the features of active disease described above. The presence of lu‐
minal narrowing with proximal bowel dilation is suggestive of fibrosis. Long-standing in‐
flammation leads to fat deposition within the submucosa of the bowel wall; this apparent
mural stratification should not be confused with the “target sign” of active disease and can
be differentiated based on the Hounsfield attenuation characteristics of fat, which is less
than 0 Housfield units (Figure 3A). Secondly, the fibrotic retraction preferentially affects the
mesenteric bowel wall, leading to the pseudosacculation appearance on the anti-mesenteric
side that can also be seen by fluoroscopy. Finally, chronic transmural Crohn’s disease, possi‐
bly due to chronic inflammatory stimulation, produces a fibrofatty proliferation of the mes‐
enteric fat, also known on CT examinations as the “creeping fat sign” (Figure 3B).
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Figure 3. CT findings in chronic Crohn’s disease. A, Fatty depositions in the submucosal layer may mimic the “target
sign” of active disease (red arrow). B, Fibrofatty proliferation of the mesenteric fat, or “creeping fat,” (red arrow) is
seen in chronic, transmural disease.
The extra-mural complications of Crohn’s disease are excellently depicted by CT. Penetrat‐
ing disease is present in approximately 20% with Crohn’s disease, with fistulas representing
the most common pathology in this category [3]. Fistulous tracts may form between any two
epithelially lined viscera in the abdomen, such as other loops of bowel (entero-enteric), the
bladder (entero-vesicular), and the skin (entero-cutaneous). A communicating tract that fills
with enteral contrast is diagnostic (Figure 4A). Evaluation with CT is highly sensitive for the
detection of fistulae, though certain anatomic locations such as the perianal region are better
imaged by MRI, as discussed below.
Figure 4. Complications of Crohn’s disease on CT. A, A fistula between two loops of small bowel is well depicted by CT
as a thin tract of oral contrast connecting the lumens of the two loops. B, An intra-abdominal abscess posterior to the
distal large bowel, likely due to a microperforation, was identified in this patient.
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Intra-abdominal abscesses are extra-luminal fluid collections that do not communicate with
the bowel (Figure 4B). The discontinuity of the abscess collection with the bowel lumen is
important to verify but can occasionally be challenging, as neural enteral contrast within the
bowel mimics the attenuation characteristics of the infected fluid within the abscess cavity.
For this reason, positive enteral contrast is often preferred to neutral contrast in patients
with suspected abscess.
3.4. Interpretation of imaging findings – Ulcerative colitis
As discussed previously, colonoscopy remains the primary approach for diagnosing and de‐
termining extent of disease in UC. However, severe complications of UC such as toxic mega‐
colon are an important indication for imaging, with CT representing the mainstay modality
in these unstable patients. CT findings include thinning of the colonic wall, luminal disten‐
sion, and pneumatosis; severe cases can lead to perforation and free intraperitoneal gas.
4. Magnetic resonance imaging
4.1. Indications
Magnetic resonance imaging enjoys many inherent advantages over other cross-sectional
imaging modalities. These include the ability to acquire images in any imaging plane, the
lack of ionizing radiation, and excellent soft tissue resolution. Because of the lack of ionizing
radiation, imaging may be performed at multiple time points during an examination, for ex‐
ample at different phases of contrast enhancement, providing a multiparametric assessment
of any particular pathology. Additionally, “cine” images can be obtained sequentially over
time, in an MRI analog to fluoroscopy.
The strengths of MRI when applied towards IBD are best suited for investigating the small
bowel and the perianal region, anatomic locations towards which Crohn’s disease demon‐
strates a tropism. Magnetic resonance imaging of the large bowel, an examination that
would have increased relevance in UC, is not routinely performed. The intrinsic spatial reso‐
lution of MRI is inferior to that of CT. An MRI examination also takes longer to complete
than a CT exam. However, the widespread adoption of new, faster MRI pulse sequences, de‐
scribed in the subsequent section, has significantly reduced scanning time and opened the
door for small bowel imaging. For specific clinical scenarios, such as perianal disease, MRI is
the recognized gold standard non-invasive technique.
4.2. Technical considerations
As with CT, multiple different MRI protocols exist for examining the abdomen. In the realm
of IBD, one very useful MR examination is magnetic resonance enterography (MRE). Al‐
though an in-depth discussion of the various pulse sequences used in abdominal MRI imag‐
ing is beyond the scope of this text, a familiarity with the commonly used sequences is
valuable in understanding the applicability of MRE. Sequences with T2 weighting are the
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best for evaluating the bowel wall. Intravenous contrast enhancement appears bright on T1
weighted sequences; however, as feces can occasionally be bright on T1 imaging too, pre-
contrast T1 image sets are obtained to help identify true enhancement. Conventional spin
echo pulse sequences do not afford the requisite temporal resolution to image the abdomen
during a single breath hold; as such, the resulting images are often degraded by respiratory
motion artifact. Beyond that, high temporal resolution is made all the more critical when in‐
vestigating a moving target as the bowel. For these reasons, MRE capitalizes on customized
MR pulse sequences that offer improved temporal resolution and are able to image the en‐
tire abdomen during a single breath hold. For example, single-shot turbo spin echo (e.g.
SSFSE or HASTE) sequences produce high quality, motion-free T2 weighted images of the
entire bowel [8]. Balanced steady state free precession sequences (e.g. FIESTA or TrueFISP)
are T1 and T2 intermediate-weighted sequences that that are rapid and demonstrate in‐
creased conspicuity of the mesentery for detection of inflammatory changes or fistula forma‐
tion [9]. These sequences, due to their rapidity, can be performed as thick slab cinematic
acquisitions to evaluate bowel peristalsis, known as MR fluoroscopy. Fat suppression is rou‐
tinely employed during both T2-weighted and T1-weighted post-contrast sequences, to
highlight areas of bowel wall edema and enhancement. The post-contrast T1 fat-suppressed
sequences are performed using 3-D techniques to accelerate image acquisition and enable
dynamic evaluation of bowel enhancement at multiple timepoints post-contrast. An average
imaging time for MRE, exclusive of the time required for enteral contrast administration, is
approximately 30-45 minutes.
Diffusion weighted imaging (DWI) is an MRI technique that has been used with tremendous
success in neurological imaging and has shown promise in gastrointestinal imaging. Diffu‐
sion imaging provides quantitative maps of the ability of water molecules in tissue to ran‐
domly move in a process known as Brownian motion. In areas of inflammation,
hypercellularity, or ischemia, the free movement of water molecules is restricted; this char‐
acteristic manifests as a low apparent diffusion coefficient (ADC) value when MRI sequen‐
ces sensitive to diffusion are obtained. Diffusion weighted imaging is at present an
experimental technique in IBD imaging (Figure 5), but initial reports have suggested that
this method may not only improve disease detection but also provide a quantitative metric
for assessing interval changes in bowel wall inflammation [10].
There is no specific bowel preparation prior to MRE, but patients generally are kept NPO for
several hours prior to the exam. Anti-peristaltic agents such as glucagon may help improve
image quality and are often administered just prior to imaging. Intravenous contrast with a
gadolinium-chelate containing agent is standardly administered. There are several options
in enteral contrast, which can be categorized by their MRI signal characteristics. “Negative”
agents are intrinsically T1 and T2 dark compounds that usually contain superparamagnetic
iron oxide particles. Their principal advantage is that they emphasize mucosal enhancement
and bowel wall edema. “Positive” agents are intrinsically T1 and T2 bright compounds;
these, similar to positive CT contrast agents, may obscure mucosal enhancement findings
and thus are infrequently used. The most commonly used class of MR enteral contrast
agents is the “biphasic” type, which are T1 dark and T2 bright (e.g. dilute barium with sorbi‐
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tol, polyethylene glycol). With these agents, one can readily assess the pattern of bowel wall
folds on T2 weighted images without losing mucosal enhancement data on T1 weighted im‐
ages [11]. Contrast agents are often hyperosmolar to maximize luminal distention; an impor‐
tant side effect for patients to be aware of is diarrhea. It is critically important that patients
ingest adequate enteric contrast for MR enterography. Unlike CT in which underdistended
bowel loops can still be evaluated, the relative diminished spatial resolution of MRI renders
collapsed bowel difficult to assess for disease. In addition, enteric contrast is needed to dis‐
place intraluminal air that can produce significant susceptibility artifact on dynamic post-
contrast MRI sequences.
Figure 5. Representative T2 (left) and diffusion weighted (right) images from an MR enterography of a child with
Crohn’s disease. Images demonstrate two colonic loops (red arrows) exhibiting bowel edema and restricted water dif‐
fusion, consistent with active inflammation.
Enteral contrast is primarily administered orally, though MR enteroclysis is also an option.
The attendant patient discomfort and added radiation from the fluoroscopy-guided place‐
ment of the naso-jejunal tube are identical to the CT analog. However, one benefit of MR
enteroclysis is the ability to perform MR fluoroscopy during the instillation of enteral con‐
trast, a technique that provides dynamic information regarding bowel distensibility.
Patients may be imaged in the supine or prone position; the latter orientation is preferred at
some institutions as the patient’s own weight is used to spread out loops of small bowel; the
compression in the anterior-posterior dimension also reduces imaging volume.
4.3. Interpretation of imaging findings – Crohn’s disease
Magnetic resonance imaging is an excellent tool for the detection of active Crohn’s disease,
with a sensitivity of > 90% [12]. Many of the imaging characteristics of active Crohn’s dis‐
ease on MRI, as one may expect, are morphologically identical to those appreciated on CT.
For example, bowel wall thickening greater than 3mm is considered abnormal and evidence
of active inflammation. Active disease with intramural edema manifests as T2 hyperintensi‐
ty between the mucosa and muscularis propria (Figure 6A) [13]. Mucosal hyperenhance‐
ment is also an important marker of active disease. Diffuse, avid, homogeneous mucosal
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enhancement is suggestive of active disease (Figure 6B). Alternatively, low-level, heteroge‐
neous mural enhancement without a mucosal component with upstream dilatation favors
the diagnosis of mural fibrosis due to irreversible collagen deposition in the bowel wall (Fig‐
ure 6C). Ulceration may be difficult to identify without proper bowel distention; ulcers ap‐
pear as thin lines of high signal intensity within thickening loops of bowel. Both MRI and
CT are insensitive for early aphthous ulcers, for which fluoroscopy or endoscopy should be
considered as more sensitive.
Figure 6. Findings of Crohn’s disease by MR enterography. A) Submucosal edema appears as T2 hyperintensity inter‐
posed between the mucosa and muscularis propria (red arrow). B) Homogeneous, avid mucosal enhancement on T1-
weighted imaging is suggestive of active disease (red arrow). C) Conversely, fixed lumimal narrowing on a T2
weighted image (red arrow, C-1) that demonstrates delayed mural enhancement on a post contrast T1 weighted im‐
age (red arrow, C-2) without a mucosal component is seen in chronic fibrosis.
Additional evidence of active disease such as the “comb sign,” in which there is engorge‐
ment of the mesenteric vessels adjacent to an inflamed loop of bowel, are well identified by
MRI. Strictures appear as a focal narrowing in the bowel lumen and are considered signifi‐
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cant if there is a pre-stenotic dilation of the proximal bowel. The so-called “creeping fat
sign” occurs in chronic, transmural inflammation, in which hypertrophy of the mesenteric
fat produces mass effect and surrounds viscera; this sign is specific for Crohn’s disease. An‐
other sign of chronic fibrosis is T2 hypointensity of the bowel wall relative to muscle.
Figure 7. MRI findings of anorectal fistulae. A, T2 hyperintensity that extends between the external and internal
sphincter complexes is diagnostic of an intersphincteric fistula (red arrow). B, Two sequential T2 weighted images
demonstrate a linear hyperintense focus traversing through the internal and external sphincter complexes consist
with a transsphincteric fistula (red arrow, B-1). The subsequent image demonstrates an associated fluid collection ex‐
tending into the left ischioanal fossa (white arrow, B-2).
Extramural disease is as conspicuous, if not more so, on MRI as it is on CT. Fistulae appear
as T2 hyperintense tracts that avidly enhance and extend from bowel to a second epithelial
lined organ such as another segment of bowel, the skin, or the bladder. Sinuses are blind-
ending tracts that extend from bowel and typically terminate within the mesentery. Both fis‐
tulae and sinuses cause translocation of gut flora out of the bowel and can be associated
with abscess formation.
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In addition to evaluating the small bowel with enterography, MRI is a powerful tool in the
investigation of perianal Crohn’s disease because of its superior soft tissue contrast for de‐
lineation of the anal sphincter complex. The lifetime risk of developing fistulous disease in
Crohn’s disease is approximately 20-40%. Anorectal fistulae are common and are classified
based on their location relative to the anal sphincter complex and pelvic floor musculature,
as anatomic location impacts upon treatment options. The most common type of anorectal
fistula is the intersphincteric fistula (Figure 7A), followed by the transphincteric fistula (Fig‐
ure 7B). The accuracy of MRI for diagnosing and classifying anorectal fistulae is comparable
to exam under anesthesia [3].
5. Ultrasound
5.1. Indications
Ultrasound is a cross-sectional imaging technique that has been used extensively in the
imaging of IBD. As with other technologies, ultrasound has its own unique set of advantag‐
es, such as low relative cost, lack of ionizing radiation, and real-time imaging capability.
Disadvantages include the inability to visualize portions of small bowel, rectum, and sig‐
moid, difficulty tracing long bowel segments, as well as operator dependence, with the qual‐
ity of the examination contingent on the technical skill of the ultrasonographer. Ultrasound
has been shown to possibly be as accurate in the diagnosis of IBD as CT and MRI based on
detection of wall thickening and hypervascularity by Doppler. However, a high sensitivity
is likely achievable only in the hands of an expert ultrasonographer, a resource that is not
widely available or easy to standardize. Ultrasound is particularly relevant in pediatric
imaging: the smaller body habitus in this patient population allows for a more complete ex‐
amination, and the lack of ionizing radiation is likely safer compared to CT. The most com‐
mon indication for ultrasound is evaluation for active inflammation in a symptomatic IBD
patient whose anatomic distribution of bowel inflammation is known.
5.2. Technical considerations
Similar to the previously described modalities, minimal patient preparation is required in
ultrasound. Since luminal gas can cause acoustic shadowing artifacts that obscure underly‐
ing structures, non-effervescent liquid may be administered to displace bowel gas distally
and provide some luminal distension. The choice of ultrasound transducer is predicated by
the patient’s body size. Higher frequency transducers produce higher resolution images but
have poorer tissue penetration compared to lower frequency transducers. Practically, an ul‐
trasonographer will begin the examination with the highest frequency transducer available,
which is usually a 15 megahertz transducer; if there are structures that are not well seen, the
ultrasonographer change to a lower frequency one.
The approach to handling the ultrasound transducer and physically tracing it across the ab‐
domen is of paramount importance. A key technique in imaging the bowel is known as
“graded compression.” Increasing pressure is applied with the transducer head as it is
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swept across the surface of the abdomen. This has the effect of displacing bowel gas and
overlying bowel loops so that the area of interest can be inspected with the greatest possible
clarity [14].
5.3. Interpretation of imaging findings
A normal segment of bowel on ultrasound exhibits five discrete layers. The inner-most layer
is a thin hyperechoic line that demarcates the interface between the lumen and the mucosa.
The next layer is a hypoechoic line at the interface between the mucosa and submucosa. The
third layer is a hyperechoic line between submucosa and the muscularis propria; this is the
most commonly involved layer in IBD. The fourth layer is the muscularis propria itself and
is hypoechoic. The fifth and final layer is hyperechoic and represents the serosa [15].
Inflammatory bowel disease is manifested on ultrasound as abnormal bowel wall thicken‐
ing, defined as greater than 3mm, and loss of definition of the discrete bowel wall layers.
Both UC and Crohn’s disease result in bowel wall thickening. However, in UC the bowel
wall layers are preserved, as opposed to Crohn’s disease; this distinction though may not be
sufficiently accurate to differentiate the two diseases by US alone. Intra-mural edema ap‐
pears as generalized hypoechogenicity within the bowel wall. Conversely, fibrostenoic dis‐
ease exhibits hyperechogenicity of the submucosal layer. Superficial ulcers may be detected
as hypoechoic interruptions within the innermost bowel wall layer.
Doppler ultrasound can provide useful adjunct data to the structural information from con‐
ventional ultrasound. Normal bowel wall, as well as fibrostenotic bowel wall, does not usu‐
ally demonstrate detectable Doppler blood flow. Therefore, the presence of intramural blood
flow is suggestive of the hyperemia of active disease.
6. Nuclear medicine/Molecular imaging
As molecule-targeted therapies become increasingly prevalent in the treatment of IBD, it is
likely that imaging their downstream effects directly via molecular imaging techniques will
play a pivotal role in the management of patients with IBD. Molecular imaging with radio‐
nuclides in IBD has been thoroughly investigated. Analogous to conventional fluoroscopy,
planar scintigraphic imaging was the predominant method of nuclear imaging for IBD in
the past, but recently tomographic techniques such as single photon emission computed to‐
mography (SPECT) and positron emission tomography (PET) have supplanted this two-di‐
mensional modality. As novel, targeted imaging agents become clinically available, it is
reasonable to expect that molecular imaging will be critical in directly tracking the efficacy
of therapies in patients with IBD in a manner that far precedes anatomic changes detectable
by conventional imaging methods.
The pathophysiology of IBD involves infiltration of gut mucosa with activated lymphocytes
and macrophages. By radiolabeling autologous white blood cells (WBCs) and re-injecting
the cells into the patient, non-invasive imaging of WBC migration into areas of inflamma‐
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tion can be achieved. The radionuclide Tc-99m has been used in such a paradigm to label
WBCs, and Tc-99m-labeled WBCs have been thoroughly investigated as a highly sensitive
and specific instrument for diagnosing IBD. Radiolabeled WBCs may also be helpful to
prognosticate response to therapy within only a few days of its initiation [16, 17].
Beyond WBCs, multiple radio-labeled probes targeting inflammation have been studied, in‐
cluding interleukins such as IL-2 and IL-8. Additionally, Annexin V, a molecular probe spe‐
cific for apoptosis, has been shown to function as an early marker of response to therapy in
patients with IBD being treated with infliximab.
The advent of positron-emitting radionuclides has paved the way for the introduction of
PET imaging into clinical practice, a modality that enjoys far greater spatial resolution than
single photon techniques. The most widely used PET imaging agent is 2-deoxy-2[18F]fluoro-
d-glucose (FDG), a radiolabeled glucose molecule that accumulates in areas of increased gly‐
colysis. Imaging with FDG-PET has a reported sensitivity and specificity for colonic mucosal
inflammation on par with endoscopy.
With the recent introduction of whole-body PET-MRI scanners, combined PET imaging with
MR enterography offers the benefits of MRI morphological assessment of diseased areas
with PET quantitation of inflammatory activity. The exquisite soft tissue differentiation of
MRI coupled with the molecular sensitivity of PET has the potential to provide unparalleled
structure-function correlation. The simultaneous acquisition of the two data sets that can be
performed with new hybrid PET-MRI systems allows for true co-registration of PET and MR
images (Figure 8); this feature is particularly relevant for abdominal imaging, as peristalsis
can result in significant changes in bowel positioning.
Figure 8. PET-MRI of patient with cecal inflammation. Fused imaging demonstrates small area of active inflammatory
changes in the cecum that would be difficult to diagnose on either FDG-PET or MR imaging independently. Images
generously provided by Drs. Alex Guimaraes, Ciprian Catana, Bruce Rosen, and David Berger (Massachusetts General
Hospital, Boston, MA).
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7. Special considerations in the pediatric population
Performing diagnostic imaging examinations on pediatric patients requires consideration of
several important factors. For example, pediatric patients may not be able to tolerate pro‐
longed examinations such as MR enterography, necessitating the use of sedation to obtain
satisfactory images. Moreover, not only are pediatric patients with IBD committed to a life‐
time of imaging studies, but also their increased percentage of actively dividing tissue and
relatively smaller body habitus render them inherently more sensitive to radiation injury
and mutagenesis compared an adult. When these risks are coupled with their baseline in‐
creased risk of malignancy due to IBD, the importance of radiation dose reduction becomes
apparent.
The association between diagnostic radiation and cancer risk is controversial. Directly
studying the effects of ionizing radiation on malignancy risk is extremely challenging. Fre‐
quently cited epidemiologic data are based on atomic bomb survivors and nuclear power
plant workers who were exposed to radiation levels that exceed those in diagnostic imaging.
Moreover, the deleterious effects of radiation likely have a prolonged incubation time, per‐
haps on the order of decades, before they are clinically apparent. A recent large retrospec‐
tive study of CT scans performed on pediatric patients suggests a measurable but small
increase in the risk of malignancy [18]. It should be noted that the radiation doses associated
with CT scans included in that study are significantly higher than current CT technique.
Nonetheless, there is little doubt that every effort should be made to reduce the radiation
exposure in pediatric patients to minimize any potential risk.
Estimating the magnitude of absorbed radiation during a CT examination can be made
through the use of phantoms. Though no patient, and especially no pediatric patient, is
identical to the standard, adult-sized body phantom, this approach remains the most quanti‐
tative means of estimating radiation levels within the body during a CT exam. However, ex‐
trapolating malignancy risk from these data is difficult, as different organs exhibit unique
susceptibilities to radiation exposure. For example, the gonads are far more radio-sensitive
than muscle tissue. For this reason, the concept of “effective dose” was introduced. This
term, measured in millisieverts (mSv), reflects an attempt to create a standard metric that
quantifies the impact of the absorbed radiation [19]. Effective dose is calculated by multiply‐
ing the absorbed radiation dose by a conversion factor for the body segment that was im‐
aged; this conversion factor varies based upon the radiosensitivity of the exposed organs.
The choice of imaging modality for IBD over the past two decades has trended towards an
increase in the use of CT. Pediatric patients may undergo multiple CT examinations over
their lifetime, and the cumulative effective dose they receive may exceed 75 mSv, a level be‐
yond which radiation-induced malignancy is felt to become an increasing concern. Patients
with Crohn’s disease are imaged far more frequently than those with UC. Also, patients
who require immunosuppressive therapy or surgery are also at a higher risk of frequent
imaging. Additional risk factors include stricturing or penetrating disease [20].
The most important avenue for reducing radiation dose is the eradication of unnecessary ex‐
aminations. Minimizing exposure time during fluoroscopy should be standard practice.
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Multiple techniques for reducing radiation dose in CT examinations have been developed
and should be implemented when imaging pediatric patients. Finally, substituting non-ion‐
izing radiation imaging modalities such as MRI and ultrasound should be considered when
appropriate.
8. Conclusions and recommendations
The modalities described in this chapter each demonstrate their own unique set of advanta‐
geous and disadvantageous features. While fluoroscopy may show superficial mucosal dis‐
ease better than any cross-sectional technique, extra-luminal disease is poorly visualized.
The high spatial and temporal resolution of CT has driven its rise in popularity over the past
two decades; however, this examination requires the use of ionizing radiation, and an ap‐
preciation of the possible associated risks is paramount prior to selecting this modality.
While MRI is more costly and time consuming, it may be the best choice in a clinical situa‐
tion where minimizing radiation dose is important or when soft tissue characterization is re‐
quired.
For imaging symptomatic patients with suspected IBD, we recommend fluoroscopic upper
GI and small bowel series because of its high sensitivity for early IBD as well as its accuracy
for diagnosing other disease entities (e.g. sprue, infectious enteritides) that can mimic IBD.
For initial imaging evaluation of newly diagnosed Crohn’s disease, as well as evaluation of
symptomatic exacerbation of known Crohn’s disease in adult patients, CT enterography is
recommended because of its superior ability to detect active bowel inflammation as well as
extraluminal and extraintestinal disease manifestations. Urgent and emergent complications
such as abscess formation and acute bowel obstruction are best imaged with traditional CT
using intravenous and no enteric contrast. Crohn’s disease patients with perianal symptoms
should be investigated with pelvic MRI. MR enteroraphy is becoming the preferred primary
imaging modality for pediatric patients, as well as adult patients who previously have un‐
dergone multiple prior CT exams, because of its lack of ionizing radiation. In patients with
longstanding IBD with persistent obstructive symptoms, MR enterography is the best imag‐
ing modality for distinguishing inflammatory from fibrotic stricture [21], which has impor‐
tant therapeutic implications. Enteroclysis techniques should generally be reserved for those
patients with remitting-relapsing obstructive symptoms despite normal enterography stud‐
ies, as a provocative examination to detect short strictures. There is likely to be an increasing
role for ultrasound in surveillance imaging in the future given its low cost and lack of re‐
quirement of sedation or oral contrast preparation.
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